

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Tetra-(p-tolyl)antimony(III)-Containing Heteropolytungstates, [(p-tolyl)Sb^{III}4(A- α -XW9O34)2]ⁿ⁻ (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1728456> since 2020-02-19T11:14:09Z

Published version:

DOI:10.1021/acs.inorgchem.9b03322

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

This is the author's final version of the contribution published as:

Ma T, Yang P, Dammann I, Lin Z, Mougharbel AS, Li MX, Adăscăliței F, Mitea R, Silvestru C, Thorstenson C, Ullrich MS, Cseh K, Jakupec MA, Keppler BK, Donalizio M, Cavalli R, Lembo D, Kortz U.

Tetra-(p-tolyl)antimony(III)-Containing Heteropolytungstates, $[\{(p\text{-tolyl})\text{SbIII}\}_4(\text{A-}\alpha\text{-XW}_9\text{O}_{34})_2]_n$ (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity

Inorg Chem. 2020 Feb 10. doi: 10.1021/acs.inorgchem.9b03322

The publisher's version is available at:

<https://pubs.acs.org/journal/inocaj>

When citing, please refer to the published version.

Link to this full text:

<http://hdl.handle.net/>

This full text was downloaded from iris-AperTO: <https://iris.unito.it/>

Tetra-*(p*-tolyl)antimony(III)-containing Containing Heteropolytungstates, $[\{(p\text{-tolyl-Tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-XW}_9\text{O}_{34})_2]^{n-}$ (X = P, As, or Ge): Synthesis, Structure, and Study of Antibacterial and Antitumor Activity

Tian Ma,^{a†} Peng Yang,^{a†} Inga Dammann,^{a†} Zhengguo Lin,^{a†} Ali S. Mougharbel,^{a†} Ming-Xing Li,^{b‡} Florin Adascalitei,^{c§} Raluca Mitea,^{c§} Cristian Silvestru,^{c§} Candice Thorstenson,^{a†} Matthias S. Ullrich,^{a†} Klaudia Cseh,^{d||} Michael A. Jakupcic,^{d||} Bernhard K. Keppler,^{d||} Manuela Donalizio,^{e⊥} Roberta Cavalli,^{f#} David Lembo,^{e⊥} and Ulrich Kortz^{*a†}

^{a†} Department of Life Sciences and Chemistry, Jacobs University, 28759 Bremen, Germany

^{b‡} Department of Chemistry, College of Sciences, Shanghai University, Shanghai 200444, P.R.P. R. China

^{c§} Department of Chemistry, Supramolecular Organic and Organometallic Chemistry Centre (SOOMCC), Faculty of Chemistry and Chemical Engineering, Babeş-Bolyai University, 400028 Cluj-Napoca, Romania


^{d||} Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, 1090 Vienna, Austria

^{e⊥} Department of Clinical and Biological Sciences, University of Turin, 10043 Orbassano, Turin, Italy

^{f#} Department of Drug Science and Technology, University of Turin, 10125 Turin, Italy

* U.K.: e-mail: u.kortz@jacobs-university.de; fax: +49 421 200 3102; tel: Telephone: +49 421 200 3235.


We have synthesized and structurally characterized three tetra-*(p*-tolyl)antimony(III)-containing heteropolytungstates, $[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-XW}_9\text{O}_{34})_2]^{n-}$ (X = P^V (**1-P**), As^V (**1-As**), or Ge^{IV} (**1-Ge**)), in aqueous solution using conventional, one-pot procedures. The polyanions **1-P**, **1-As**, and **1-Ge** were fully characterized in the solid state and in solution and were shown to be soluble and stable in aqueous medium at pH 7. Biological studies showed that all three polyanions display significant antibacterial and antitumor activities. The minimum inhibitory concentration (MIC) concentrations of **1-P**, **1-As**, and **1-Ge** were determined against four kinds of bacteria, including the two pathogenic bacteria strains, *Vibrio parahaemolyticus* and *Vibrio vulnificus*. The three novel polyanions also showed high cytotoxic potency in the human cell lines A549 (non-small cell lung cancer), CH1/PA-1 (ovarian teratocarcinoma), and SW480 (colon carcinoma).



Abstract Graphic

We have synthesized three tetra-*(p*-tolyl)antimony(III)-containing heteropolytungstates, $[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-XW}_9\text{O}_{34})_2]^{n-}$ (X = P (**1-P**), As (**1-As**), or Ge (**1-Ge**)), which were characterized in the solid state and in solution by a multitude of analytical techniques. The biological assays demonstrated antibacterial

activities of the novel polyanions and a higher antiproliferative activity against tumor cells than human foreskin fibroblasts.



TOC Graphic

Keywords: Polyoxometalates; organometallic chemistry; antimony; antibacterial; anticancer

196537119653721965373

SI File: ic9b03322 si 001.pdf

INTRODUCTION Introduction

Polyoxometalates (POMs) are discrete, polynuclear metal oxides with enormous structural and compositional variety, and a multitude of properties which are of interest in fundamental and applied science.¹ The incorporation of organometallic moieties such as organophosphorus(V),² organosilicon(IV),³ organogermanium(IV),⁴ organoruthenium(II),⁵ and organotin(IV),⁶ in lacunary (vacant) heteropolytungstates may allow the modification of the shape, size, lipophilicity, solubility, stability, toxicity as well as, and redox and acid–base properties of POMs. Furthermore, from a biomedical point of view, it is possible to tune POMs for antimicrobial, antiviral, and antitumor properties, as well as protein crystallography.⁷

Organoantimony compounds, which are known to possess properties relevant for the fields of catalysis⁸ and biology⁹ (albeit less than organotin compounds), are usually synthesized by the self-condensation of arylstibonic acid.¹⁰ In recent years, our group has developed the class of organoantimony-containing POMs, and it was demonstrated that these compounds were shown to exhibit structure-dependent antibacterial activity. In 2012, the discrete phenylantimony(III)-containing heteropolytungstates [(PhSb^{III})₄(A- α -PW₉O₃₄)₂]¹⁰⁻, [(PhSb^{III})₄(A- α -GeW₉O₃₄)₂]¹²⁻, and [2-(Me₂NCH₂C₆H₄)Sb^{III}]₃(B- α -As^{III}W₉O₃₃)¹³⁻ were reported. All three compounds are soluble and stable in aqueous solution at physiological pH and they exhibit activity against both *Escherichia coli* and *Bacillus subtilis*.¹¹ Considering that the organo–Sb(III) species themselves are not water-soluble renders the POM as an inorganic vehicle for the bioactive component, which does not exclude the possibility that the shape and size of the polyanion contribute to this activity, as well. In some follow-up work, we studied the dependence of the POM bioactivity on the type and number of organoantimony groups,¹² and it became apparent that the biological activity of the POM increases with (i) the number of incorporated organoantimony(III) groups and (ii) the type of functional group attached to the antimony atom. Interestingly, the complete absence of any organic moiety completely inactivates the bioactivity of the POM.

To date, only a handful of organoantimony(III)-containing POMs have been synthesized and structurally characterized.^{11–13} Here, we report on the synthesis and characterization of three tetra-*p*-tolylantimony(III)-containing POMs and their bioactivity.

EXPERIMENTAL SECTION Experimental Section

Materials and Physical Measurements

The lacunary POM precursors Na₉[A- α -PW₉O₃₄]·7H₂O,^{14a} Na₉[A- α -AsW₉O₃₄]·18H₂O,^{14b} and Na₉[A- α -HGeW₉O₃₄]·23H₂O,^{14c} and the organoantimony(III) species (*p*-tolyl)SbCl₂,¹⁵ were prepared according to the literature. The other reagents were obtained from commercial sources and used as received without further purification. Infrared (IR) spectra were recorded on a Nicolet-Avatar 370 FT-IR spectrometer using KBr pellets in the range of 400–4000 cm⁻¹ range. Elemental analyses were performed by Institut des Sciences Analytiques, CNRS, Villeurbanne, France (CHN only), and CREALINS, Villeurbanne, France (all other elements), respectively. Thermogravimetric analyses (TGA) were performed on a TA Instruments SDT Q600 thermobalance at a heating rate of 10 °C min⁻¹ under a N₂ atmosphere. The nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz instrument (JEOL, Model ECS 400) at room temperature, using 5 mm tubes for ¹H, ¹³C, and ³¹P NMR, and 10

mm tubes for ^{183}W NMR, with resonance frequencies of 399.78 MHz (^1H), 100.71 MHz (^{13}C), 162.14 MHz (^{31}P), and 16.69 MHz (^{183}W), respectively. The chemical shifts are reported with respect to the references $\text{Si}(\text{CH}_3)_4$ (^1H and ^{13}C), 85% H_3PO_4 (^{31}P), and 1M M aqueous Na_2WO_4 (^{183}W), respectively.

Synthesis of $\text{Rb}_5.5\text{Na}_{4.5}[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-PW}_9\text{O}_{34})_2]\cdot 40\text{H}_2\text{O}$ (**RbNa-1-P**)

$\text{Na}_9[A\text{-}\alpha\text{-PW}_9\text{O}_{34}]\cdot 7\text{H}_2\text{O}$ (0.050 mmol, 0.128 g) was dissolved in 12 mL of a 0.5 M NaOAc/AcOH solution (pH 5.6), and then (*p*-tolyl) SbCl_2 (0.050 mmol, 0.0142 g) dissolved in 3 mL of ethanol was added dropwise under vigorous stirring. The solution color changed from colorless to light yellow. The resulting solution was stirred for 20 min, and then the pH was adjusted from 7.6 to 6.5 by adding 0.5 M HCl_{aq} . The bright solution was stirred for another additional 20 min and filtered, and then a few drops of 1M M RbCl_{aq} were added. This solution was placed in a refrigerator at $4\text{--}5\text{ }^\circ\text{C}$. Yellow, rod-shaped crystals of **RbNa-1-P** were obtained after 3 days, which were filtered off and air-dried. Yield: 0.078 g (47 % based on W). Elemental analysis. Calcd (%): ~~Calcd:~~ Sb, 7.37; W, W 50.1050.10; P, P 0.940.94; Na, Na 1.57; Rb, 7.12; C, 5.10. Found (%): Sb, 7.21; W, W 48.9248.92; P, P 0.930.93; Na, Na 1.89; Rb, 7.42; C, 5.47. IR (2% KBr pellet, cm^{-1}): 1189 (w), 1072 (s), 1010 (m), 943 (s), 916 (s), 889 (m), 808 (s), 740 (s), 634 (m), 592 (m), 572 (m), 513 (m), 487 (m), 451 (sh), 418 (m).

Synthesis of $(\text{NH}_4)_{9.5}\text{Na}_{0.5}[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-AsW}_9\text{O}_{34})_2]\cdot 40\text{H}_2\text{O}$ (**NH₄Na-1-As**)

$\text{Na}_9[A\text{-}\alpha\text{-AsW}_9\text{O}_{34}]\cdot 18\text{H}_2\text{O}$ (0.050 mmol, 0.140 g) was dissolved in 12 mL of water, and then (*p*-tolyl) SbCl_2 (0.050 mmol, 0.0142 g) dissolved in 3 mL of ethanol was added dropwise under vigorous stirring. The solution color changed from colorless to light yellow. The resulting solution was stirred for 20 min, and then the pH was adjusted from 7.6 to 7.0 by adding 0.5 M HCl_{aq} . The bright solution was stirred for another additional 20 min and filtered, and then a few drops of 1M M $\text{NH}_4\text{Cl}_{\text{aq}}$ were added. This solution was placed in a refrigerator at $4\text{--}5\text{ }^\circ\text{C}$. Yellow, needle-shaped crystals of **NH₄Na-1-As** were obtained after 1 week, which were filtered off and air-dried. Yield: 0.086 g (55 % based on W). Elemental analysis. Calcd (%): ~~Calcd:~~ Sb, 7.73; W, W 52.5152.51; As, As 2.382.38; Na, Na 0.18; N, 2.22; C, 5.34. Found (%): Sb, 7.83; W, W 51.1051.10; As, As 2.442.44; Na, Na 0.21; N, 2.31; C, 5.83. IR (2% KBr pellet, cm^{-1}): 1156 (w), 1062 (w), 950 (m), 881 (s), 852 (s), 810 (s), 804 (s), 732 (s), 638 (m), 572 (w), 518 (w), 485 (w), 463 (sh), 441 (w), 418 (w).

Synthesis of $\text{Rb}_6\text{Na}_6[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-GeW}_9\text{O}_{34})_2]\cdot 40\text{H}_2\text{O}$ (**RbNa-1-Ge**)

$\text{Na}_9[A\text{-}\alpha\text{-HGeW}_9\text{O}_{34}]\cdot 23\text{H}_2\text{O}$ (0.050 mmol, 0.145 g) was dissolved in 12 mL of 0.5 M NaOAc/AcOH buffer (pH 7.0), and then (*p*-tolyl) SbCl_2 (0.050 mmol, 0.0142 g) dissolved in 3 mL of ethanol was added dropwise under vigorous stirring. The solution color changed from colorless to light yellow. The resulting solution was stirred for 20 min, and then the pH was adjusted from 7.6 to 7.0 by adding 0.5 M HCl_{aq} . The bright yellow solution was stirred for another additional 20 min and filtered, and then a few drops of 1M M RbCl_{aq} were added. This solution was placed in a refrigerator at $4\text{--}5\text{ }^\circ\text{C}$. Yellow, rod-shaped crystals of **RbNa-1-Ge** were obtained after 3 days, which were filtered off and air-dried. Yield: 0.092 g (54 % based on W). Elemental analysis. Calcd (%): ~~Calcd:~~ Sb, 7.11; W, W 48.3248.32; Ge, Ge 2.122.12; Na, Na 2.35; Rb, 7.48; C, 5.26. Found (%): Sb, 6.67; W, W 47.8947.89; Ge, Ge 1.891.89; Na, Na 2.63; Rb, 7.51; C, 5.83. IR (2% KBr pellet, cm^{-1}): 1189 (w), 1064 (w), 927 (m), 875 (m), 806 (sh), 779 (s), 721 (s), 632 (m), 572 (w), 534 (w), 485 (m), 441 (w).

X-ray Crystallography

The single-crystal X-ray diffraction data of **1-P**, **1-As**, and **1-Ge** were collected on a Bruker Kappa X8 APEX II CCD diffractometer with graphite monochromatic $\text{Mo K}\alpha$ radiation ($\lambda = 0.71073\text{ \AA}$) at 100 K. An empirical absorption correction was applied using the SADABS program.¹⁶ The SHELX software package (Bruker) was used to solve and refine the structures.¹⁷ The structures were solved by direct methods and refined by the full-matrix least-squares method ($\sum w(F_o - F_c)^2$) with anisotropic thermal parameters for all heavy atoms included in the model. The hydrogen atoms of the organic groups were introduced in geometrically calculated positions. The H atoms of the crystal waters were not located. It was not possible to locate all counter cations/counteranions by XRD, due to severe crystallographic disorder, which is a common problem in POM crystallography. Therefore, the exact number of counter cations/counteranions and crystal waters in the compounds was determined by elemental analysis, and the resulting formula units were further used throughout the paper and in the CIF file for overall consistency. In the Supporting Information, the crystal data and structure refinement for the three compounds are summarized in Table S1, and selected bond lengths and angles are listed in Tables S2 and S3. Cambridge Crystallographic Data files CCDC 1965373–1965373 (**NaRb-1-P**), CCDC 1965371–1965371 (**NaNH₄-1-As**), and CCDC 1965372–1965372 (**NaRb-1-Ge**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/.

Antibacterial Activity: Determination of Minimal Inhibitory Concentrations (MICs) for Bacterial Cells

The MIC studies were conducted in MHB media and followed our earlier work.¹¹ The Gram-positive bacteria *Bacillus subtilis*, as well as the Gram-negative bacteria *Escherichia coli* K12, *Vibrio parahaemolyticus*, and *V. vulnificus* were used in the assay. *Vibrio* species are well-known pathogens to not only humans, but also economically important aquaculture stocks. In 2016, Vezzulli et al. described an increasing abundance of pathogenic *Vibrio* species in temperate and cold regions, such as the North Sea, with warming sea surface water temperatures.¹⁸ Two North Sea isolates of *V. parahaemolyticus* and *V. vulnificus* were chosen to represent their closely related human-pathogenic strains in the MIC. The starting concentration of polyanions **1-P**, **1-As**, and **1-Ge** and the phenylantimony(III)-analogues $\text{Rb}_9\text{Na}[(\text{PhSb}^{\text{III}})_4(\text{A}-\alpha\text{-PW}_9\text{O}_{34})_2] \cdot 20\text{H}_2\text{O}$ (**RbNa-2-P**),¹¹ $\text{Cs}_{6.5}\text{Na}_{3.5}[(\text{PhSb}^{\text{III}})_4(\text{A}-\alpha\text{-AsW}_9\text{O}_{34})_2] \cdot 36\text{H}_2\text{O}$ (**CsNa-2-As**),^{12c} and $(\text{NH}_4)_{12}[(\text{PhSb}^{\text{III}})_4(\text{A}-\alpha\text{-GeW}_9\text{O}_{34})_2] \cdot 20\text{H}_2\text{O}$ (**NH 4-2-Ge**),¹¹ in deionized water used in the MIC assay plates was 10 mg mL^{-1} . The MIC was conducted in triplicate for each strain and polyanion.

Antitumor Activity: Cytotoxicity Tests in Human Cancer Cells

Cells and culture conditions Culture Conditions. Three different human cancer cell lines, A549 (non-small cell lung cancer), CH1/PA-1 (ovarian teratocarcinoma), and SW480 (colon carcinoma), were used for cytotoxicity determination to determine cytotoxicity. A549 and SW480 cells were kindly provided by Brigitte B. Marian, (Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Vienna, Austria). CH1/PA-1 cells were provided by Lloyd L. R. Kelland, (CRC Center for Cancer Therapeutics, Institute of Cancer Research, Sutton, U.K.). All cell culture media, supplements, and reagents were purchased from Sigma-Aldrich, unless stated otherwise. Cells were grown as adherent monolayer cultures in minimal essential medium (MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; from BioWest), 4 mM L-glutamine, 1 mM sodium pyruvate, and 1% (v/v) non-essential amino acids (from 100x to 100x solution). The cultures were kept at 37 °C in a humidified incubator in an atmosphere containing 5% CO₂ in air. Human Foreskin Fibroblasts (HFF-1) (ATCC® SCRC-1041) at a low passage number (less than <30) were grown as monolayers in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, Saint Louis, MO, U.S.A.) supplemented with 15% heat-inactivated FBS (Sigma-Aldrich) and a 1% antibiotic solution (Penicillin-Streptomycin™ streptomycin, Sigma-Aldrich).

Cell Viability Assay. The IC₅₀ (50% inhibitory concentration) values of the tested polyanions on tumor cells were determined by means of the colorimetric MTT (thiazolyl blue tetrazolium bromide) staining method. Three different cell densities were plated into 96-well plates (Starlab International GmbH, Hamburg, Germany), depending on the cell line: 3×10^3 A549 cells/well, 1×10^3 CH1/PA-1 cells/well, and 2×10^3 SW480 cells/well, each in volumes of 100 µL/well. After a 24 h pre-incubation, cells were treated in triplicate with a range of concentrations of the polyanions dissolved directly in MEM. After a 96 h incubation at 37 °C, the medium from each well was replaced with 100 µL of 6:1 RPMI 1640 medium (supplemented with 10% heat-inactivated FBS and 1 mM sodium pyruvate) / MTT solution (250 mg of MTT in 50 mL of Dulbecco's phosphate-buffered saline (PBS)). The plates were incubated for a further 4 h, and the resultant formazan crystals were dissolved in 150 µL of DMSO. The absorbance was determined spectrophotometrically at 550 nm with a microplate reader (ELx880, BioTek) using a reference wavelength of 690 nm. All tests comprised at least three independent experiments. The cell viability was measured in HFF-1 cells using the MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay, as described by Cavalli et al. in 2012.¹⁹ HFF-1 cells were seeded in 96-well plates at a density of 7×10^3 , 6×10^3 , and 5×10^3 cells/well and incubated with serial concentrations of the polyanions, ranging from 100 µM to 0.015 µM, for 24, 48, and 72 hours, respectively. Cell viability was determined by the CellTiter 96® Proliferation Assay Kit (Promega, Madison, WI, USA) according to the manufacturer's instructions, and absorbances were measured by Multiskan™ FC Microplate photometer (ThermoScientific, USA) at 490 nm. The effect on cell viability at different concentrations was expressed as a percentage, by comparing absorbances of treated cells with those of cells incubated with culture medium alone. The IC₅₀ and 95% confidence intervals (CIs) were determined using Prism software (Graph-Pad Software, San Diego, CA, USA).

Apoptosis assay Assay. Induction of programmed cell death by the compounds was determined by the flow-cytometric annexin V/PI assay. SW480 cells were seeded in 24-well plates (Starlab) at a density of 7×10^4 cells in 600 µL of complete MEM per well. After a 24 h pre-incubation, cells were treated with different concentrations (0.016 µM, 0.08 µM, 0.4 µM, and 2 µM) of the tested polyanions, dissolved directly in the medium.


Only for polyanion **2-Ge** were higher concentrations (50 μM , 10 μM , 2 μM , and 0.4 μM) were used, due to the higher IC_{50} values. After exposure for 24 h at 37 $^{\circ}\text{C}$, the supernatant of each well was collected, and the cells were trypsinized and mixed with the supernatant. The cells were pelleted by centrifugation (300 g , for 3 min), and the supernatant was removed. Then, the cells were resuspended with FITC-conjugated annexin V (0.4 $\mu\text{g}/\text{mL}$) (BioVision) in binding buffer ([10 mM HEPES/NaOH (pH 7.4), 140 mM NaCl, and 2.5 mM CaCl_2]) and incubated at 37 $^{\circ}\text{C}$ for 15 min. The staining with propidium iodide (1.6 $\mu\text{g}/\text{mL}$) (PI, Fluka) was done performed shortly before the measurement with a Millipore guava easyCyte 8 HT flow cytometer and InCyte software. The received dot plots were analyzed with the FlowJo software (TreeStar).

RESULTS AND DISCUSSION Results and Discussion


Structural Characterization


The polyanion [$\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-AsW}_9\text{O}_{34})_2\}^{10-}$ (**1-As**) was prepared by reaction of $(p\text{-tolyl})\text{SbCl}_2$ with the POM precursor salt $\text{Na}_9[A\text{-}\alpha\text{-AsW}_9\text{O}_{34}] \cdot 18\text{H}_2\text{O}$ in water. The $(p\text{-tolyl})\text{SbCl}_2$ was first dissolved in 3 mL of ethanol and then added dropwise to an aqueous solution of the lacunary POM precursor. The product was isolated as the mixed ammonium–sodium salt $(\text{NH}_4)_{9.5}\text{Na}_{0.5}[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-AsW}_9\text{O}_{34})_2] \cdot 40\text{H}_2\text{O}$ (**NH₄Na-1-As**). The isostructural polyanions [$\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-PW}_9\text{O}_{34})_2\}^{10-}$ (**1-P**) and [$\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-GeW}_9\text{O}_{34})_2\}^{12-}$ (**1-Ge**) were synthesized equally by reaction of $(p\text{-tolyl})\text{SbCl}_2$ with the relevant sodium salts of the lacunary POM precursors $\text{Na}_9[A\text{-}\alpha\text{-PW}_9\text{O}_{34}] \cdot 7\text{H}_2\text{O}$ and $\text{Na}_9[A\text{-}\alpha\text{-HGeW}_9\text{O}_{34}] \cdot 23\text{H}_2\text{O}$ in 0.5 M NaOAc/AcOH solutions at pH 6.5 and 7, respectively. The polyanions were then crystallized as mixed rubidium–sodium salts, resulting in $\text{Rb}_{5.5}\text{Na}_{4.5}[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-PW}_9\text{O}_{34})_2] \cdot 40\text{H}_2\text{O}$ (**RbNa-1-P**) and $\text{Rb}_6\text{Na}_6[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-GeW}_9\text{O}_{34})_2] \cdot 40\text{H}_2\text{O}$ (**RbNa-1-Ge**), respectively. The X-ray structural analysis revealed that **1-P**, **1-As**, and **1-Ge** are isostructural and they crystallize in the triclinic crystal system, in space group $P\bar{1}$. The three polyanions comprise four $(p\text{-tolyl})\text{Sb}^{\text{III}}$ groups sandwiched by two $\{A\text{-}\alpha\text{-XW}_9\text{O}_{34}\}$ ($X = \text{P, As, or Ge}$) Keggin fragments, resulting in a structure with idealized C_{2h} symmetry (see Fig. Figure 1). Each Sb^{III} atom is tetra-coordinated tetraordinated by two oxygens of one Keggin unit, one oxygen of the other Keggin unit, and a C atom of the terminal tolyl group. This results in a see-saw seesaw geometry with the bulky $p\text{-tolyl}$ groups pointing outside the polyanion, leaving space on the inside for the lone pair of electrons. The bond lengths of $\text{Sb}-\text{O}$ [2.014(7)–2.411(11) \AA] and $\text{Sb}-\text{C}$ [2.112(10)–2.192(7) \AA] bond lengths are within the usual ranges. Bond valence sum (BVS) calculations confirm that the oxidation state of all antimony atoms is +3.²⁰ The $\text{Sb} \cdots \text{Sb}$ distances for the three polyanions are 3.56 \AA for **1-As** and **1-P** and 3.57 \AA for **1-Ge** (see Figure 1). The phenyl derivatives of **1-As**, **1-P**, and **1-Ge** are also known, [$(\text{PhSb}^{\text{III}})_4(A\text{-}\alpha\text{-XW}_9\text{O}_{34})_2\}^{n-}$ ($X = \text{P}$ (**2-P**), **As** (**2-As**), or **Ge** (**2-Ge**)).^{11,12c}

Figure 1. (a) Combined polyhedral/ball-and-stick representation of [$\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-XW}_9\text{O}_{34})_2\}^{n-}$] ($X = \text{P}$ (**1-P**), **As** (**1-As**), or **Ge** (**1-Ge**)). (b) Top view of the positions of the four antimony atoms describing a rectangle. Color code: WO_6 , red octahedra; heteroatom X, purple; Sb, green; C, gray; H, black balls.



Equations for the synthesis of **1-P**, **1-As**, and **1-Ge** are shown below, and they indicate that the ideal molar ratio of the reagents $(p\text{-tolyl})\text{SbCl}_2$ and trilacunary POM precursor should be 2:1.





The yield following such a stoichiometry was only around 10%. However, when using an equimolar ratio, the yield increased to 47–55%. Numerous control experiments revealed that the key factors affecting the yields for polyanions **1-As**, **1-P**, and **1-Ge** are solvent (water vs sodium acetate buffer) and pH.

Infrared (IR) Spectroscopy

Fourier-transform infrared (FT-IR) spectra were recorded on **RbNa-1-P**, **NH₄Na-1-As**, and **RbNa-1-Ge** were recorded (see Supporting Information, Figures S1–S3). The stretching and bending vibrations of the C–H and C–C bonds of the *p*-tolyl groups appear at 1189, 1072, and 740 cm⁻¹ for **1-P**, in the range of 1156, 1062, and 732 cm⁻¹ for **1-As**, and 1189, 1064, and 721 cm⁻¹ for **1-Ge**. For **1-P**, the band at 1072 cm⁻¹ corresponds to the P–O stretching mode. The band at 852 cm⁻¹ corresponds to the As–O stretching mode for **1-As**, whereas the band at 875 cm⁻¹ corresponds to the Ge–O stretching mode for **1-Ge**. The peaks below 1000 cm⁻¹ are attributed to the terminal W=O bonds as well as the bridging W–O–W stretching modes for all three polyanions.


Thermogravimetric Analysis

We investigated the thermal stability of **RbNa-1-P**, **NH₄Na-1-As**, and **RbNa-1-Ge** by thermogravimetric analysis (TGA), (see the Supporting Information, Figure S4). The experiments were performed in the temperature range of 20–800 °C under a N₂ atmosphere. Several weight-loss steps were observed for all three compounds. The first step in the range of 20–140 °C is associated with the loss of crystal waters. The number of crystal waters determined by TGA was slightly lower than that found by elemental analysis. The reason could be the drying of the samples at room temperature prior to the measurements. For **1-As**, the second weight-loss step in the range of 140–400 °C can be assigned to the loss of all four tolyl groups and six NH₃ molecules per formula unit (7.5% found vs 7.5% calculated). Some of the other NH₃ molecules are possibly lost already below 140 °C. For **1-P** and **1-Ge**, it was difficult to determine the exact weight loss steps for the organic groups. The total weight losses for **1-As**, **1-P**, and **1-Ge** at 800 °C were 20.4%, 15.8%, and 17.6%, respectively.

Multinuclear NMR Spectroscopy


The solution stability of polyanions **1-P**, **1-As**, and **1-Ge** was investigated by multinuclear NMR spectroscopy after redissolution of the solid salts in water. The ¹⁸³W NMR spectra of **1-P** (–101.7, –113.1, –115.6, –168.2, and –177.4 ppm) and **1-As** (–83.0, –90.0, –109.4, –144.8, and –173.3 ppm) showed the expected five peaks with intensity ratios of 2:1:2:2:2 and 2:2:1:2:2, respectively, which is fully consistent with the C_{2h} point group symmetry of the polyanions in the solid state (see Figure 2). No ¹⁸³W NMR spectrum could be obtained for **1-Ge** due to the low solubility of this compound.

Figure 2. ¹⁸³W NMR spectra of **1-P** (left) and **1-As** (right) recorded in H₂O/D₂O at room temperature.



The ^{31}P NMR spectrum of **1-P** displayed the expected singlet at -11.2 ppm (see Figure 3). The ^{13}C NMR spectra of **1-P**, **1-As**, and **1-Ge** were as expected, indicating the coordinated *p*-tolyl groups (Figure S5). The ^1H NMR spectra of **1-P**, **1-As**, and **1-Ge** also showed the presence of the *p*-tolyl groups (Figure S6). Additionally, time-dependent ^1H NMR spectra were recorded for all three compounds, and demonstrated their stability in aqueous solution for at least 5 days (Figure S7). The reagent (*p*-tolyl) SbCl_2 is not soluble in aqueous solution, and hence, no NMR studies could be performed in this solvent.

Figure 3. ^{31}P NMR spectrum of **1-P** recorded in $\text{H}_2\text{O}/\text{D}_2\text{O}$ at room temperature.



Antibacterial Activity: Determination of Minimal Inhibitory Concentrations (MIC/MICs) for Bacterial Cells

The antibacterial activities of the three lacunary POM precursors [*A*- α - PW_9O_{34}] $^{9-}$, [*A*- α - $\text{AsW}_9\text{O}_{34}$] $^{9-}$, and [*A*- α - $\text{HGeW}_9\text{O}_{34}$] $^{9-}$ and their {(*p*-tolyl) Sb^{III} } derivatives **1-P**, **1-As**, and **1-Ge** against four different kinds of bacteria (*E. coli*, *B. subtilis*, *V. parahaemolyticus*, and *V. vulnificus*) are listed in Table 1. All three POM precursors showed no inhibition against bacterial growth. In contrast, the {(*p*-tolyl) Sb^{III} } substituted polyanions **1-P**, **1-As**, and **1-Ge** successfully inhibited the selected bacterial strains. The bioactivities of these were compared with that of our earlier reported isostructural tetraphenylantimony-phenylantimony-containing polyanions **2-P**, **2-As**, and **2-Ge**, respectively (see Table S4).^{11,12c} Our results demonstrate that the three novel polyanions **1-P**,

1-As and **1-Ge** exhibit a similar inhibitory activity against the four bacterial strains similar to those of the phenyl-Sb-containing analogues **2-P**, **2-As**, and **2-Ge**. While the former showed a minimum inhibitory concentration (MIC) in the range of 15.6–62.5 µg/mL, the MICs for the latter ranged from 15.6 to 110 µg/mL (see Table S4). Thus, the relationship between the type of organic group (*p*-tolyl vs phenyl) attached to the polyanions and their apparent biological activity is supported by these findings. We show the MIC results of all organo-Sb^{III}-containing heteropolytungstates against the growth of *E. coli* and *B. subtilis* in Table 2, which is arranged by increasing antibacterial activity. The three novel (*p*-tolyl)Sb^{III}-containing **1-P**, **1-As**, and **1-Ge** exhibit the strongest bioactivity of all known organoantimony-containing POMs.

To date, we have explored organoantimony POMs with three different types of organic groups attached to Sb^{III}, such as phenyl, (*ortho*-Me₂NCH₂)phenyl (Hyp), and *para*-tolyl. We have shown in earlier work that the phenyl-Sb POMs display significantly higher antibacterial activity than their isostructural Hyp-Sb analogues.^{12b} Hence it appears that *ortho*-functionalization of the phenyl ring is not promising. Furthermore, bioactivity increases with the number of the organic groups attached to the polyanion.^{12a} On the other hand, in the absence of any organo group on Sb^{III} the bioactivity of the resulting polyanion is very poor.^{12c} Our current work demonstrates that *para*-functionalization of the phenyl ring results in even slightly better bioactivity than for the phenyl-Sb POMs. As the *para* position on the phenyl ring protrudes away from the polyanion and is well exposed to the biotarget it appears likely that even larger *para*-substituents such as ethyl or iso-propyl might be even more effective.

Table 1. Minimal Inhibitory Concentrations (MICs) for different polyanions against the growth of bacteria.

	MIC determination ^a (µg/mL) (µg/ml)			
	1-P	1-As	1-Ge	[XW ₉ O ₃₄] ⁿ⁻
Gram-positive				
<i>Bacillus subtilis</i>	15.6	15.6	15.6	— ^a
Gram-negative				
<i>Escherichia coli</i>	62.5	31.2	15.6	—
<i>Vibrio parahaemolyticus</i>	15.6	31.2	15.6	—
<i>V. vulnificus</i>	15.6	15.6	15.6	—

^aNo bacterial inhibition was found for the three lacunary POM precursors.

Table 2. Minimal Inhibitory Concentrations (MICs) of various organoantimony-containing heteropolytungstates against the growth of *Escherichia coli* and *Bacillus subtilis*.

	MIC determination ^a (µg/mL) (µg/ml)			
Organoantimony(III)-containing POMs	<i>B. subtilis</i>	<i>E. coli</i>		Ref
[Na{2-(Me ₂ NH ⁺ CH ₂)C ₆ H ₄ Sb ^{III} }; As ^{III}] ₂ W ₁₉ O ₆₇ (H ₂ O)] ¹⁰⁻ κ(1-Hyp)^I(1-Hyp)	250	1000		12b
[(Sb ^{III} OH) ₄ (4- <i>α</i> -AsVW ₉ O ₃₄) ₂] ¹⁰⁻ κ(1-SbOH)^I(1-SbOH)	250	1000		12c

Organoantimonyorganoantimony(III)-containing POMs	<i>B. subtilis</i>	<i>E. coli</i>	Refref
$[\{2-(\text{Me}_2\text{HN}^+\text{CH}_2)\text{C}_6\text{H}_4\text{Sb}^{\text{III}}\}_2\text{As}^{\text{III}}_2\text{W}_{19}\text{O}_{67}(\text{H}_2\text{O})\}^{\text{8-}}]$ (2-Hyp)^T (2-Hyp)	250	500	12b
$[(\text{PhSb}^{\text{III}})\{\text{Na}(\text{H}_2\text{O})\}\text{As}^{\text{III}}_2\text{W}_{19}\text{O}_{67}(\text{H}_2\text{O})\}^{\text{11-}}]$ (1-PhSb)^T (1-PhSb)	125	500	12a
$[(\text{PhSb}^{\text{III}})_2\text{As}^{\text{III}}_2\text{W}_{19}\text{O}_{67}(\text{H}_2\text{O})\}^{\text{10-}}]$ (2-PhSb)^T (2-PhSb)	62.5	250	12a
$[\{2-(\text{Me}_2\text{HN}^+\text{CH}_2)\text{C}_6\text{H}_4\text{Sb}^{\text{III}}\}_3(\text{B-}\alpha\text{-As}^{\text{III}}\text{W}_9\text{O}_{33})\}^{\text{3-}}]$ (3-Hyp)^T (3-Hyp)	60	130	11
$[(\text{PhSb}^{\text{III}})_3(\text{B-}\alpha\text{-As}^{\text{III}}\text{W}_9\text{O}_{33})_2\}^{\text{12-}}]$ (3-PhSb)^T (3-PhSb)	62.5	125	12a
$[(\text{PhSb}^{\text{III}})_4(\text{A-}\alpha\text{-PW}_9\text{O}_{34})_2\}^{\text{10-}}]$ (2-P)^T (2-P)	50	110	11
$[(\text{PhSb}^{\text{III}})_4(\text{A-}\alpha\text{-GeW}_9\text{O}_{34})_2\}^{\text{12-}}]$ (2-Ge)^T (2-Ge)	80	80	11
$[(\text{PhSb}^{\text{III}})_4(\text{A-}\alpha\text{-As}^{\text{V}}\text{W}_9\text{O}_{34})_2\}^{\text{10-}}]$ (2-As)^T (2-As)	15.6	62.5	12c
$[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(\text{A-}\alpha\text{-PW}_9\text{O}_{34})_2\}^{\text{10-}}]$ (1-P)^T (1-P)	15.6	62.5	This work
$[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(\text{A-}\alpha\text{-As}^{\text{V}}\text{W}_9\text{O}_{34})_2\}^{\text{10-}}]$ (1-As)^T (1-As)	15.6	31.3	This work
$[\{(p\text{-tolyl})\text{Sb}^{\text{III}}\}_4(\text{A-}\alpha\text{-GeW}_9\text{O}_{34})_2\}^{\text{11-}}]$ (1-Ge)^T (1-Ge)	15.6	15.6	This work

To date, we have explored organoantimony-containing POMs with three different types of organic groups attached to Sb^{III} , such as phenyl, (*o*- Me_2NCH_2)phenyl (Hyp), and *p*-tolyl. We have shown in earlier work that the phenyl-Sb POMs display antibacterial activity significantly higher than those of their isostructural Hyp-Sb analogues.^{12b} Hence it appears that *ortho* functionalization of the phenyl ring is not promising. Furthermore, bioactivity increases with the number of organic groups attached to the polyanion.^{12a} On the other hand, in the absence of any organo group on Sb^{III} , the bioactivity of the resulting polyanion is very poor.^{12c} Our current work demonstrates that *para* functionalization of the phenyl ring results in even slightly better bioactivity than for the phenyl-Sb POMs. As the *para* position on the phenyl ring protrudes away from the polyanion and is well exposed to the biotarget, it appears likely that even larger *para* substituents such as ethyl or isopropyl might be even more effective.

Cytotoxicity in Cancer Cells

The cytotoxic potency of **1-P**, **1-As**, and **1-Ge** in human tumor cell lines was investigated. The first POM-based example of that type was reported in 1965 by Mukherjee, using a mixture of $\text{H}_3[\text{PW}_{12}\text{O}_{40}]$ and caffeine for the treat-

ment of gastrointestinal cancer.²¹ The high toxicity of purely inorganic POMs restricts their clinical application. Organic-inorganic hybrid POMs are conceived as potential anticancer reagents.^{6f} Here we investigated the cytotoxic effects of six organoantimony-containing POMs, the novel **1-P**, **1-As**, and **1-Ge** and the phenyl-analogues **2-P**, **2-As**, and **2-Ge**, against A549 (non-small cell lung cancer), CH1/PA-1 (ovarian teratocarcinoma), and SW480 (colon carcinoma) cells by using an MTT assay.

In general, the cytotoxic potency of the novel *p*-tolylantimony(III)-containing polyanions **1-P**, **1-As**, and **1-Ge** is higher in the broadly chemosensitive ovarian carcinoma (CH1/PA-1) and in colon carcinoma (SW480) cells (with promising IC₅₀ values mostly in the two-digit nanomolar range) than in the more chemoresistant non-small lung cancer (A549) cell line (Table 3). All three **1-P**, **1-As**, and **1-Ge** all showed similar cytotoxicity, which was higher in all of the investigated cell lines than that of the three phenylantimony(III)-containing analogues **2-P**, **2-As**, and **2-Ge** (with **2-Ge** showing the lowest potency by far), (see Figure 4). Interestingly, all six investigated polyanions exerted a significantly lower antiproliferative activity in human foreskin fibroblasts that was significantly lower than the activity observed in cancer cells, indicating a specific antitumor activity (Table 4). Only **2-Ge** exhibited a higher IC₅₀ value in one cell line (A549) than the value obtained in HFF-1. As reported in Table 4, the three *p*-tolyl-POMs **1-P**, **1-As**, and **1-Ge** exerted a variable effect on the viability of human foreskin fibroblasts generating dose-response curves. Among them, polyanion **1-Ge** was the least toxic, showing the highest IC₅₀ values, ranging from 3.16 μM to 1.92 μM over time, exerting a minor cell alteration; polyanion **1-As** exhibited the lowest value of IC₅₀ (<1 μM) at all of the time points analyzed. The cells treated with **1-P**, **1-As**, and **1-Ge** displayed an increasing phenotypical cell alteration microscopically over time. The dose-response curves for the phenyl-derivatives **2-P**, **2-As**, and **2-Ge** indicated that **2-Ge** affected the cell viability the least at the 24-hour interval time point, exhibiting a significantly higher IC₅₀ value (2.05 μM) significantly higher than those of both **2-P** and **2-As** with IC₅₀ values of 1.37 μM and 1.35 μM, respectively. At 72-hour post-treatment, all three phenyl-derivatives exhibited similar effects on cell viability, with IC₅₀ values of 3.55 μM, 3.98 μM, and 3.54 μM for **2-P**, **2-Ge**, and **2-As**, respectively. Overall, the performed experiments suggest that for organoantimony-containing POMs, the presence of the phenyl group is associated with a minor effect on cell viability compared with the corresponding *p*-tolyl group, with the exception of **2-Ge** at 24 hours. Indeed, the phenyl-derivative **2-As** exhibited significantly less cytotoxicity than the corresponding *p*-tolyl-derivative **1-As** at all of the time points investigated (*p* < 0.0001).

Table 3. IC₅₀ values of the investigated polyanions for three different cancer cell lines after incubation for 96 hours.

Compound	IC ₅₀ (μM) ^a		
	A549	CH1/PA-1	SW480
1-P	0.20 ± 0.02	0.0097 ± 0.0006	0.0093 ± 0.0032
1-As	0.21 ± 0.02	0.010 ± 0.002	0.010 ± 0.003
1-Ge	0.28 ± 0.03	0.010 ± 0.002	0.016 ± 0.004
2-P	0.62 ± 0.09	0.037 ± 0.005	0.025 ± 0.005
2-As	0.53 ± 0.02	0.031 ± 0.002	0.019 ± 0.002
2-Ge	17 ± 2	0.29 ± 0.02	0.82 ± 0.22

^aMean 50 % inhibitory concentration ± the standard deviation in A549, CH1/PA-1, and SW480 cell lines, determined by the MTT assay.

Figure 4. Concentration-effect curves of polyanions **1-P**, **1-As**, **1-Ge**, **2-P**, **2-As**, and **2-Ge** in A549, CH1/PA-1, and SW480 cells, determined by the MTT assay (96 h exposure). The dashed lines denote the 50% inhibitory level.




Table 4. Inhibitory concentration-50 (IC_{50} , μM) Values and 95% confidence interval values Confidence Interval Values for 1-P, 1-As, and 1-Ge and the phenyl derivatives Phenyl Derivatives 2-P, 2-As, and 2-Ge at 24, 48, and 72 hours post-treatment after Treatment in HFF-1 cells.Cells

Compound compound	IC_{50} (μM) ^a		
	24 hpth	48 hpth	72 hpth
1-P	1.44 (K(1.27-1.62)) ^T 1.27-1.62)	1.12 (K(0.79-1.59)) ^T 0.79-1.59)	1.34 (K(1.08-1.66)) ^T 1.08-1.66)
1-As	0.53 (K(0.46-0.59)) ^T 0.46-0.59)	0.58 (K(0.43-0.77)) ^T 0.43-0.77)	0.82 (K(0.66-1.01)) ^T 0.66-1.01)
1-Ge	3.16 (K(2.84-3.52)) ^T 2.84-3.52)	2.03 (K(1.23-3.31)) ^T 1.23-3.31)	1.92 (K(1.75-2.10)) ^T 1.75-2.10)
2-P	1.37 (K(1.28-1.45)) ^T 1.28-1.45)	2.38 (K(0.06-5.17)) ^T 0.06-5.17)	3.55 (K(2.92-4.32)) ^T 2.92-4.32)
2-As	1.35 (K(1.26-1.44)) ^T 1.26-1.44)	3.33 (K(2.59-4.27)) ^T 2.59-4.27)	3.54 (K(2.80-4.47)) ^T 2.80-4.47)
2-Ge	2.05 (K(1.83-2.28)) ^T 1.83-2.28)	3.72 (K(3.12-4.43)) ^T 3.12-4.43)	3.98 (K(3.27-4.84)) ^T 3.27-4.84)

^aMean 50 % inhibitory concentration and 95% confidence interval (CI) in the HFF-1 cell line, determined by the MTS assay.


Apoptosis assay

SW480 cells were exposed to the polyanions to determine the extent of apoptosis induction induced by annexin V-FITC/PI staining and flow cytometry. Polyanions 1-P, 1-As, 1-Ge, 2-P and 2-As at a concentration of 2 μM induced apoptosis in a very high percentage of cells, ranging from 84% to 93% after a 24 h exposure (Table S6 and


Figure 5). At a concentration of 0.4 μM , the highest level of induced apoptosis induction (46% and 49%) was detected for two of the phenylantimony(III)-containing heteropolytungstates (**2-P** and **2-As**). In the case of the three *p*-tolylantimony(III)-containing heteropolytungstates (**1-P**, **1-As**, and **1-Ge**), apoptosis was pronounced, with percentages ranging between from 22% and to 30% (Figure S8). **2-Ge** showed the lowest capacity of apoptosis induction, which correlates very well with the measured IC_{50} values.

Figure 5. SW480 cells were labeled with annexin V-FITC and PI to analyze the induction of apoptosis by **1-P**, **1-As**, **1-Ge**, **2-P**, **2-As**, and **2-Ge** after 24 h. Depicted are dot plots from flow cytometric analysis of samples exposed to the highest concentration of the studied compounds (2 μM , except for **2-Ge** (50 μM)). The upper left quadrants represent necrotic (Q1; AV-/PI+), the upper right quadrants late apoptotic (Q2; AV+/PI+), the lower right quadrants early apoptotic (Q3; AV+/PI-), and the lower left quadrants viable (Q4; AV-/PI-) cell fractions. One representative experiment out of three is shown.


untreated
control




1-P




1-As




1-Ge




2-P



2-As



2-Ge



CONCLUSIONS

We have prepared the three dimeric, sandwich-type tetra-(*p*-tolyl)Sb-containing heteropoly-18-tungstates $[\{(p\text{-tolyl)Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-PW}_9\text{O}_{34})_2]^{10-}$ (**1-P**), $[\{(p\text{-tolyl)Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-AsW}_9\text{O}_{34})_2]^{10-}$ (**1-As**), and $[\{(p\text{-tolyl)Sb}^{\text{III}}\}_4(A\text{-}\alpha\text{-Ge}^{\text{IV}}\text{W}_9\text{O}_{34})_2]^{12-}$ (**1-Ge**), which were characterized by single-crystal XRD, FT-IR, and multinuclear (^1H , ^{13}C , ^{31}P ,

and ^{183}W) NMR in solution. The novel **1-P**, **1-As**, and **1-Ge** and their phenyl analogues **2-P**, **2-As**, and **2-Ge** have been explored for antibacterial and *in vitro* anticancer activity. This is the first study to test the antimicrobial effect of these compounds against the human pathogens *V. parahaemolyticus* and *V. vulnificus*. Furthermore, all six polyanions exhibited antiproliferative potency against A549 (non-small cell lung cancer), CH1/PA-1 (ovarian teratocarcinoma), and SW480 (colon carcinoma) cells, but it was higher for **1-P**, **1-As**, and **1-Ge** than for the phenyl analogues **2-P**, **2-As**, and **2-Ge**. The activity of all six polyanions is specific against tumor cells, since because a lower cytotoxic effect was observed in the HFF-1 cell line. The reason for the different bioactivity between the (*p*-tolyl)Sb-containing polyanions **1-P**, **1-As**, and **1-Ge** and the isostructural PhSb-containing polyanions **2-P**, **2-As**, and **2-Ge** appears to be due to an increased lipophilic character by due to methyl functionalization of the phenyl group in the *para* position. Our work demonstrates an important step forward in the goal to synthesize of synthesizing polyanions with improved bioactivity and to unravel their mechanism of action.

Supporting Information

Supporting Information

Synthesis of (*p*-tolyl)SbCl₂; FT-IR spectra (Figures S1–3); TGA thermograms (Figure S4); ¹H (Figure S6), and ¹³C NMR spectra (Figure S5), as well as time-dependent ¹H NMR spectra (Figure S7). Early/late apoptosis and necrosis induction after 24 h in SW480 cells, analyzed by flow cytometry and averaged over three independent experiments (Figure S8). Tables with the main crystallographic and refinement parameters (Tables S1–S3), as well as MIC determination of the polyanions against the growth of bacteria (Table S4). Percentages of early/late apoptosis and necrosis induction by the investigated polyanions **1-P**, **1-As**, **1-Ge**, **2-P**, **2-As** and **2-Ge** in SW480 cells after exposure for 24 h (Table S5). This material is available free of charge via the Internet at <http://pubs.acs.org> <https://pubs.acs.org/doi/10.1021/acs.inorgchem.9b03322>.

Synthesis of (*p*-tolyl)SbCl₂; FT-IR spectra (Figures S1–S3); TGA thermograms (Figure S4); ¹H (Figure S6) and ¹³C NMR (Figure S5) spectra and time-dependent ¹H NMR spectra (Figure S7); early/late apoptosis and necrosis induction after 24 h in SW480 cells, analyzed by flow cytometry and averaged over three independent experiments (Figure S8); tables of the main crystallographic and refinement parameters (Tables S1–S3) and MICs of the polyanions against the growth of bacteria (Table S4); and percentages of early/late apoptosis and necrosis induction by the investigated polyanions **1-P**, **1-As**, **1-Ge**, **2-P**, **2-As**, and **2-Ge** in SW480 cells after exposure for 24 h (Table S5) (PDF)

Accession Codes CCDC 1965371–1965373 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

Notes

The authors declare no competing financial interest.

Acknowledgments. U.K. thanks the German Science Foundation (DFG-KO-2288/20-1 and DFG-KO-2288/26-1) and Jacobs University for research support. T.M. and P.Y. acknowledge the China Scholarship Council (CSC) for a doctoral fellowship. Z.L. thanks the National Natural Science Foundation of China (21701010) for research support. F.A., R.M., and C.S. gratefully acknowledge the financial support from the National Research Council (CNCS) of Romania, through Research Project No. PN-II-ID-PCE-2011-3-0933. U.K. also acknowledges CMST COST Action CM1203 (PoCheMoN). Figure 1 was generated with Diamond, version 3.2 (copyright Crystal Impact GbR).

References

- (1) (a) Pope, M. T. *Heteropoly and Isopoly Oxometalates*; Springer-Verlag: Berlin, 1983. (b) Barras-Almenar, J. J.; Coronado, E.; Müller-Müller, A.; Pope, M. T. *Polyoxometalate Molecular Science*; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2004. (c) Pope, M. T.; Kortz, U. Polyoxometalates. In *Encyclopedia of Inorganic and Bioinorganic Chemistry*; John Wiley, 2012.
- (2) (a) Mayer, C. R.; Thouvenot, R. Organophosphoryl derivatives of trivalent tungstophosphates of general formula $\alpha\text{-A}[\text{PW}_9\text{O}_{34}(\text{RPO})_2]^{5-}$: synthesis and structure determination by multinuclear magnetic resonance spectroscopy (³¹P, ¹⁸³W). *J. Chem. Soc., Dalton Trans.* **1998**, *1*, 7–14 [10.1039/a705216b](https://doi.org/10.1039/a705216b). (b) Sun, Z.-G.; Liu, Q.; Liu, J.-F. Synthesis and spectroscopic characterization of organophosphoryl polyoxotungstates $[\text{C}_6\text{H}_{11}\text{P}(\text{O})_2\text{X}^{n+}\text{W}_{10}\text{O}_{39}^{(8-n)-}]$ ($\text{X}^{n+}=\text{P}^{5+}$,

Si⁴⁺, B³⁺, Ga³⁺). *Polyhedron* **2000**, *19*, 125–128 [10.1016/S0277-5387\(99\)00326-5](https://doi.org/10.1016/S0277-5387(99)00326-5). (c) Sun, Z.-G.; Liu, Q.; Liu, J.-F. Organophosphoryl polyoxotungstates α -[R₂PW₉O₃₄]⁵⁻ [R = PhP(S), C₆H₁₁P(O), H₂NCH(n-Pr)P(O)]. *Transition Metal Chemistry/Met. Chem.* **2000**, *25*, 374–376 [10.1023/A:1007049514031](https://doi.org/10.1023/A:1007049514031). (d) Sun, Z.-G.; Zhang, L.-C.; Liu, Z.-M.; Cui, L.-Y.; Tian, C.-H.; Liang, H.-D.; Zhu, Z.-M.; You, W.-S. Synthesis, spectroscopic properties and crystal structure of organophosphoryl polyoxotungstate α -[Bu₄N]₃H[PhCH₂P(O)]₂SiW₁₁O₃₉. *J. Coord. Chem.* **2006**, *59*, 1557–1564 [10.1080/00958970600561423](https://doi.org/10.1080/00958970600561423). (e) Carraro, M.; Modugno, G.; Sartorel, A.; Scorrano, G.; Bonchio, M. Optically Active Polyoxotungstates Bearing Chiral Organophosphonate Substituents. *Eur. J. Inorg. Chem.* **2009**, *342009*, 5164–5174 [10.1002/ejic.200900728](https://doi.org/10.1002/ejic.200900728).

(3) (a) Mayer, C. R.; Cabuil, V.; Lalot, T.; Thouvenot, R. Incorporation of Magnetic Nanoparticles in New Hybrid Networks Based on Heteropolyanions and Polyacrylamide. *Angew. Chem., Int. Ed.* **1999**, *38*, 3672–3675 [10.1002/\(SICI\)1521-3773\(19991216\)38:24<3672::AID-ANIE3672>3.0.CO;2-#](https://doi.org/10.1002/(SICI)1521-3773(19991216)38:24<3672::AID-ANIE3672>3.0.CO;2-#). (b) Mayer, C. R.; Lalot, T.; Thouvenot, R. Hybrid Hydrogels Obtained by the Copolymerization of Acrylamide with Aggregates of Methacryloyl Derivatives of Polyoxotungstates. A Comparison with Polyacrylamide Hydrogels with Trapped Aggregates. *Macromolecules* **2000**, *33*, 4433–4437 [10.1021/ma991918h](https://doi.org/10.1021/ma991918h). (c) Niu, J.-Y.; Li, M.-X.; Wang, J.-P. Organosilyl derivatives of trivacant tungstophosphate of general formula α -A-[PW₉O₃₄(RSiO)₃(RSi)]³⁻: Synthesis and structure determination by X-ray crystallography. *J. Organomet. Chem.* **2003**, *675*, 84–90 [10.1016/S0022-328X\(03\)00252-3](https://doi.org/10.1016/S0022-328X(03)00252-3). (d) Mayer, C. R.; Roch-Marchal, C.; Lavanant, H.; Thouvenot, R.; Sellier, N.; Blais, J. C.; Secheresse, F. New Organosilyl Derivatives of the Dawson Polyoxometalate [α -P₂W₁₇O₆₁(RSi)₂O]⁶⁻: Synthesis and Mass Spectrometric Investigation. *Chem. - Eur. J. Chem.* **2004**, *10*, 5517–5523 [10.1002/chem.200400217](https://doi.org/10.1002/chem.200400217). (e) Kato, C. N.; Kasahara, Y.; Hayashi, K.; Yamaguchi, A.; Hasegawa, T.; Nomiya, K. Syntheses, Characterization, and X-ray Crystal Structures of Mono-Lacunary Dawson Polyoxometalate-Based Organosilyl Complexes. *Eur. J. Inorg. Chem.* **2006**, *232006*, 4834–4842 [10.1002/ejic.200600479](https://doi.org/10.1002/ejic.200600479). (f) Proust, A.; Thouvenot, R.; Gouzerh, P. Functionalization of polyoxometalates: towards advanced applications in catalysis and materials science. *Chem. Commun.* **2008**, *16*, 1837–1852 [10.1039/b715502f](https://doi.org/10.1039/b715502f). (g) Zhang, T.; Mazaud, L.; Chamoreau, L.-M.; Paris, C.; Proust, A.; Guillemot, G. Unveiling the Active Surface Sites in Heterogeneous Titanium-Based Silicalite Epoxidation Catalysts: Input of Silanol-Functionalized Polyoxotungstates as Soluble Analogues. *ACS Catal.* **2018**, *8*, 2330–2342 [10.1021/acscatal.8b00256](https://doi.org/10.1021/acscatal.8b00256).

(4) (a) Knoth, W. H. Derivatives of heteropolyanions. 1. Organic derivatives of W₁₂SiO₄₀⁴⁻, W₁₂PO₄₀³⁻, and Mo₁₂SiO₄₀⁴⁻. *J. Am. Chem. Soc.* **1979**, *101*, 759–760 [10.1021/ja00497a057](https://doi.org/10.1021/ja00497a057). (b) Knoth, W. H. Derivatives of heteropolyanions. 2. Metal-metal-bonded derivatives. *J. Am. Chem. Soc.* **1979**, *101*, 2211–2213 [10.1021/ja00502a052](https://doi.org/10.1021/ja00502a052). (c) Zonnevillje, F.; Pope, M. T. Attachment of organic groups to heteropolyoxometalate anions. *J. Am. Chem. Soc.* **1979**, *101*, 2731–2732 [10.1021/ja00504a040](https://doi.org/10.1021/ja00504a040). (d) Sazani, G.; Pope, M. T. Organotin and organogermanium linkers for simple, direct functionalization of polyoxotungstates. *Dalton Trans.* **2004**, *0*, 1989–1994 [10.1039/b402421d](https://doi.org/10.1039/b402421d). (e) Joo, N.; Renaudineau, S.; Delapierre, G.; Bidan, G.; Chamoreau, L.-M.; Thouvenot, R.; Gouzerh, P.; Proust, A. Organosilyl/-germyl Polyoxotungstate Hybrids for Covalent Grafting onto Silicon Surfaces: Towards Molecular Memories. *Chem. - Eur. J.* **2010**, *16*, 5043–5051 [10.1002/chem.200903336](https://doi.org/10.1002/chem.200903336). (f) Nomiya, K.; Togashi, Y.; Kasahara, Y.; Aoki, S.; Seki, H.; Noguchi, M.; Yoshida, S. Synthesis and Structure of Dawson Polyoxometalate-Based, Multifunctional, Inorganic–Organic Hybrid Compounds: Organogermeryl Complexes with One Terminal Functional Group and Organosilyl Analogues with Two Terminal Functional Groups. *Inorg. Chem.* **2011**, *50*, 9606–9619 [10.1021/ic201336v](https://doi.org/10.1021/ic201336v).

(5) (a) Artero, V.; Proust, A.; Herson, P.; Villain, F.; Cartier dit Moulin, C. C.-d.; Gouzerh, P. Synthesis and characterization of the first carbene derivative of a polyoxometalate. *J. Am. Chem. Soc.* **2003**, *125*, 11156–11157 [10.1021/ja036257p](https://doi.org/10.1021/ja036257p). (b) Laurencin, D.; Villanneau, R.; Herson, P.; Thouvenot, R.; Jeannin, Y.; Proust, A. Proust, A. A new organometallic heteropolytungstate related to [Sb₂W₂₂O₇₄(OH)₂]¹²⁻: synthesis and structural characterisation of the bis-{Ru(*p*-cymene)}²⁺-containing anion [Sb₂W₂₀O₇₀{Ru(*p*-cymene)}₂]¹⁰⁻. *Chem. Commun.* **2005**, 5524–5526 [10.1039/b510300b](https://doi.org/10.1039/b510300b). (c) Bi, L.-H.; Kortz, U.; Dickman, M. H.; Keita, B.; Nadjo, L. Trilacunary Heteropolytungstates Functionalized by Organometallic Ruthenium(II), [(RuC₆H₆)₂XW₉O₃₄]⁶⁻ (X = Si, Ge). *Inorg. Chem.* **2005**, *44*, 7485–7493 [10.1021/ic0508627](https://doi.org/10.1021/ic0508627). (d) Sadakane, M.; Imuro, Y.; Tsukuma, D.; Bassil, B. S.; Dickman, M. H.; Kortz, U.; Zhang, Y.; Ye, S.; Ueda, W. Carbonyl–ruthenium substituted α -Keggin-tungstosilicate, [α -SiW₁₁O₃₉Ru^{II}(CO)]⁶⁻: synthesis, structure, redox studies and reactivity. *Dalton Trans.* **2008**, 6692–6698 [10.1039/b810987g](https://doi.org/10.1039/b810987g). (e) Meng, R.-Q.; Suo, L.; Hou, G.-F.; Liang, J.; Bi, L.-H.; Li, H.-L.; Wu, L.-X.

Organo-Ru supported sandwich-type tungstoarsenates: Synthesis, structure and catalytic properties. *CrystEngComm* **2013**, *15*, 5867–5876 [10.1039/c3ce00045a](https://doi.org/10.1039/c3ce00045a). (f) Abramov, P. A.; Sokolov, M. N.; Floquet, S.; Haouas, M.; Taulelle, F.; Cadot, E.; Peresyphkina, E. V.; Virovets, A. V.; Vicent, C.; Kompankov, N. B.; Zhdanov, A. A.; Shuvaeva, O. V.; Fedin, V. P. Coordination-Induced Condensation of $[\text{Ta}_6\text{O}_{19}]^{8-}$: Synthesis and Structure of $[\{(\text{C}_6\text{H}_6)\text{Ru}\}_2\text{Ta}_6\text{O}_{19}]^{4-}$ and $[\{(\text{C}_6\text{H}_6)\text{RuTa}_6\text{O}_{18}\}_2(\mu\text{-O})]^{10-}$. *Inorg. Chem.* **2014**, *53*, 12791–12798 [10.1021/ic501622t](https://doi.org/10.1021/ic501622t).

(6) (a) Knoth, W. H.; Harlow, R. L. Derivatives of heteropolyanions. 3. O-alkylation of $\text{Mo}_{12}\text{PO}_{40}^{3-}$ and $\text{W}_{12}\text{PO}_{40}^{3-}$. *J. Am. Chem. Soc.* **1981**, *103*, 4265–4266 [10.1021/ja00404a056](https://doi.org/10.1021/ja00404a056). (b) Bareyt, S.; Piligkos, S.; Hasenknopf, B.; Gouzerh, P.; Lacôte, E.; Thorimbert, S.; Malacria, M. Highly Efficient Peptide Bond Formation to Functionalized Wells-Dawson-Type Polyoxotungstates. *Angew. Chem., Int. Ed.* **2003**, *42*, 3404–3406 [10.1002/anie.200351346](https://doi.org/10.1002/anie.200351346). (c) Kortz, U.; Hussain, F.; Reicke, M. The Ball-Shaped Heteropolytungstates $[\{\text{Sn}(\text{CH}_3)_2(\text{H}_2\text{O})\}_{24}\{\text{Sn}(\text{CH}_3)_2\}_{12}(\text{A-XW}_9\text{O}_{34})_{12}]^{36-}$. *Angew. Chem., Int. Ed.* **2005**, *44*, 3773–3777 [10.1002/anie.200500548](https://doi.org/10.1002/anie.200500548). (d) Izzet, G.; Ménand, M.; Matt, B.; Renaudineau, S.; Chamoreau, L.-M.; Sollogoub, M.; Proust, A. Cyclodextrin-Induced Auto-Healing of Hybrid Polyoxometalates. *Angew. Chem., Int. Ed.* **2012**, *51*, 487–490 [10.1002/anie.201106727](https://doi.org/10.1002/anie.201106727). (e) Sang, X.-J.; Li, J.-S.; Zhang, L.-C.; Zhu, Z.-M.; Chen, W.-L.; Li, Y.-G.; Su, Z.-M.; Wang, E.-B. Two carboxyethyltin functionalized polyoxometalates for assembly on carbon nanotubes as efficient counter electrode materials in dye-sensitized solar cells. *Chem. Commun.* **2014**, *50*, 14678–14681 [10.1039/C4CC06211F](https://doi.org/10.1039/C4CC06211F). (f) Han, Q.; Liu, J.-C.; Wen, Y.; Chen, L.-J.; Zhao, J.-W.; Yang, G.-Y. Tellurotungstate-based organotin–rare-earth heterometallic hybrids with four organic components. *Inorg. Chem.* **2017**, *56*, 7257–7269 [10.1021/acs.inorgchem.7b00924](https://doi.org/10.1021/acs.inorgchem.7b00924).

(7) (a) Pope, M. T.; Müller, A. *Polyoxometalate: from Platonic Solids to Antiviral Activity*; Kluwer Academic Publishers: Dordrecht, The Netherlands, 1994. (b) Gouzerh, P.; Proust, A. Main-group element, organic, and organometallic derivatives of polyoxometalates. *Chem. Rev.* **1998**, *98*, 77–111 [10.1021/cr960393d](https://doi.org/10.1021/cr960393d). (c) Rhule, J. T.; Hill, C. L.; Judd, D. A.; Schinazi, R. F. Polyoxometalates in medicine. *Chem. Rev.* **1998**, *98*, 327–358 [10.1021/cr960396q](https://doi.org/10.1021/cr960396q). (d) Dolbecq, A.; Dumas, E.; Mayer, C. R.; Mialane, P. Hybrid organic–inorganic polyoxometalate compounds: from structural diversity to applications. *Chem. Rev.* **2010**, *110*, 6009–6048 [10.1021/cr1000578](https://doi.org/10.1021/cr1000578). (e) Bijelic, A.; Rompel, A. The use of polyoxometalates in protein crystallography—An attempt to widen a well-known bottleneck. *Coord. Chem. Rev.* **2015**, *299*, 22–38 [10.1016/j.ccr.2015.03.018](https://doi.org/10.1016/j.ccr.2015.03.018). (f) Bijelic, A.; Aureliano, M.; Rompel, A. Polyoxometalates as potential next-generation metallodrugs in the combat against cancer. *Angew. Chem., Int. Ed.* **2018**, *57*, 22980–22999 [10.1002/anie.201803868](https://doi.org/10.1002/anie.201803868). (g) Bijelic, A.; Aureliano, M.; Rompel, A. The antibacterial activity of polyoxometalates: structures, antibiotic effects and future perspectives. *Chem. Commun.* **2018**, *54*, 1153–1169 [10.1039/C7CC07549A](https://doi.org/10.1039/C7CC07549A). (h) Čolović, M.; Lačković, M.; Lalatović, J.; Mougharbel, A. S.; Kortz, U.; Krstić, D. Z. Polyoxometalates in Biomedicine: Update and Overview. *Curr. Med. Chem.* **2020**, *27*, 1535–1553 [10.2174/0929867326666190827153532](https://doi.org/10.2174/0929867326666190827153532). (i) Yang, P.; Ma, T.; Lang, Z.-L.; Misirlic-Dencic, S.; Isaković, A. M.; Benyei, A.; Čolović, M. B.; Markovic, I.; Krstić, D. Z.; Poblet, J. M.; Lin, Z.-G.; Kortz, U. Tetravalent Metal Ion Guests in Polyoxopalladate Chemistry: Synthesis and Anticancer Activity of $[\text{MO}_8\text{Pd}_{12}(\text{PO}_4)_8]^{12-}$ (M = Sn^{IV} , Pb^{IV}). *Inorg. Chem.* **2019**, *58*, 11294–11299 [10.1021/acs.inorgchem.9b01129](https://doi.org/10.1021/acs.inorgchem.9b01129). (j) Gott, M.; Yang, P.; Kortz, U.; Stephan, H.; Pietzsch, H.-J.; Mamat, C. A ^{224}Ra -labeled polyoxopalladate as a putative radiopharmaceutical. *Chem. Commun.* **2019**, *55*, 7631–7634 [10.1039/C9CC02587A](https://doi.org/10.1039/C9CC02587A). (k) Francese, R.; Civra, A.; Ritta, M.; Donalizio, M.; Argenziano, M.; Cavalli, R.; Mougharbel, A. S.; Kortz, U.; Lembo, D. Anti-zika virus activity of polyoxometalates. *Antivir. Res.* **2019**, *163*, 29–33 [10.1016/j.antiviral.2019.01.005](https://doi.org/10.1016/j.antiviral.2019.01.005).

(8) Huang, Y.-Z. Synthetic applications of organoantimony compounds. *Acc. Chem. Res.* **1992**, *25*, 182–187 [10.1021/ar00016a002](https://doi.org/10.1021/ar00016a002).

(9) Haiduc, I.; Silvestru, C. Metal compounds in cancer chemotherapy. *Coord. Chem. Rev.* **1990**, *99*, 253–296 [10.1016/0010-8545\(90\)80065-2](https://doi.org/10.1016/0010-8545(90)80065-2).

(10) (a) Silvestru, C.; Haiduc, I. Structural patterns in inorganic and organoantimony derivatives of oxo- and thiodiorganophosphorus ligands. *Coord. Chem. Rev.* **1996**, *147*, 117–146 [10.1016/0010-8545\(95\)01129-3](https://doi.org/10.1016/0010-8545(95)01129-3). (b) Prabhu, M. S. R.; Jami, A. K.; Baskar, V. Organoantimony(V) Oxido Cubane Cluster $[(p\text{-X-C}_6\text{H}_4\text{Sb})_4(\text{O})_4(\text{Ph}_2\text{SiO}_2)_4]$ (X = Cl, Br) Stabilized by Diphenyldisiloxides. *Organometallics* **2009**, *28*, 3953–3956 [10.1021/om900244t](https://doi.org/10.1021/om900244t). (c) Nicholson, B. K.; Clark, C. J.; Wright, C. E.; Groutso, T. Isopolyoxometalates of Antimony: Arylstibonic Acids $[\text{H}_8(\text{RSb})_{12}\text{O}_{28}]$ and Derived Dodecanuclear Polyoxostibonates $[\text{M}_2\text{H}_{10-x}(\text{RSb})_{12}\text{O}_{30}]^{x-}$, M = Na or K. *Organometallics* **2010**, *29*, 6518–6526 [10.1021/om1008692](https://doi.org/10.1021/om1008692). (d) Jami, A. K.; Prabhu, M. S. R.; Baskar, V. Isolation

of tetranuclear organoantimony oxo clusters and hexa-decanuclear polyoxostibonates. *Organometallics* **2010**, *29*, 1137–1143 [10.1021/om900942q](https://doi.org/10.1021/om900942q). (e) Nicholson, B. K.; Clark, C. J.; Wright, C. E.; Telfer, S. G.; Groutso, T. New Sb₁₂ and Sb₁₄ Polyoxometalate Frameworks Derived from Arylstibonic Acids: [LiH₃(*p*-MeC₆H₄Sb)₁₂O₂₈]⁴⁻ and [BaH₁₀(*p*-MeC₆H₄Sb)₁₄O₃₄]. *Organometallics* **2011**, *30*, 6612–6616 [10.1021/om200739a](https://doi.org/10.1021/om200739a).

(11) Barsukova-Stuckart, M.; Piedra-Garza, L. F.; Gautam, B.; Alfaro-Espinoza, G.; Izarova, N. V.; Banerjee, A.; Bassil, B. S.; Ullrich, M. S.; Breunig, H. J.; Silvestru, C.; Kortz, U. Synthesis and biological activity of organoantimony (III)-containing heteropolytungstates. *Inorg. Chem.* **2012**, *51*, 12015–12022 [10.1021/ic301892s](https://doi.org/10.1021/ic301892s).

(12) (a) Yang, P.; Bassil, B. S.; Lin, Z.; Haider, A.; Alfaro-Espinoza, G.; Ullrich, M. S.; Silvestru, C.; Kortz, U. Organoantimony (III)-Containing Tungstoarsenates (III): From Controlled Assembly to Biological Activity. *Chem. Eur. J.* **2015**, *21*, 15600–15606 [10.1002/chem.201502398](https://doi.org/10.1002/chem.201502398). (b) Yang, P.; Lin, Z.; Alfaro-Espinoza, G.; Ullrich, M. S.; Rat, C. I.; Silvestru, C.; Kortz, U. 19-Tungstodiarsenate (III) Functionalized by Organoantimony (III) Groups: Tuning the Structure–Bioactivity Relationship. *Inorg. Chem.* **2016**, *55*, 251–258 [10.1021/acs.inorgchem.5b02189](https://doi.org/10.1021/acs.inorgchem.5b02189). (c) Yang, P.; Lin, Z.; Bassil, B. S.; Alfaro-Espinoza, G.; Ullrich, M. S.; Li, M.-X.; Silvestru, C.; Kortz, U. Tetra-Antimony(III)-Bridged 18-Tungsto-2-Arsenates(V), [(LSb^{III})₄(A-α-As^VW₉O₃₄)₂]¹⁰⁻ (L = Ph, OH): Turning Bioactivity On and Off by Ligand Substitution. *Inorg. Chem.* **2016**, *55*, 3718–3720 [10.1021/acs.inorgchem.6b00107](https://doi.org/10.1021/acs.inorgchem.6b00107).

(13) (a) Liu, B.-Y.; Ku, Y.-T.; Wang, M.; Wang, B.-Y.; Zheng, P.-J. A New Type of Organostibonic Molybdate. Synthesis and Structure of a Tetra-*n*-butylammonium Salt of Diphenylstibonomolybdate. *J. Chem. Soc., Chem. Commun.* **1989**, 651–652 [10.1039/c39890000651](https://doi.org/10.1039/c39890000651). (b) Piedra-Garza, L. F.; Dickman, M. H.; Moldovan, O.; Breunig, H. J.; Kortz, U. Organoantimony-Containing Polyoxometalate: [{PhSbOH}₃(A-α-PW₉O₃₄)₂]⁹⁻. *Inorg. Chem.* **2009**, *48*, 411–413 [10.1021/ic8021694](https://doi.org/10.1021/ic8021694).

(14) (a) Domaille, P. J. Potassium octadecatungstodiphosphates (V) and related lacunary compounds. *Inorg. Synth.* **1990**, *27*, 100. (b) Contant, R.; Thouvenot, R.; Dromzee, Y.; Proust, A.; Gouzerh, P. Synthesis and structural chemistry of tungstoarsenates (V). *J. Cluster Sci.* **2006**, *17*, 317–331 [10.1007/s10876-006-0054-0](https://doi.org/10.1007/s10876-006-0054-0). (c) Herve, G.; Teze, A. Study of alpha.-and beta.-enneatungstosilicates and-germanates. *Inorg. Chem.* **1977**, *16*, 2115–2117 [10.1021/ic50174a060](https://doi.org/10.1021/ic50174a060).

(15) (a) Talalaeva, T.V.I. V.; Kocheshkov, K. A. Synthesis of antimony organic compounds by lithium organic compounds. *Russ. J. Gen. Chem.* **1946**, *16*, 777–780. (b) Nunn, M.; Sowerby, D.B.D. B.; Wesolek, D.M.D. M. The preparation of phenyl substituted antimony (III) and antimony (V) chlorides and bromides. *J. Organomet. Chem.* **1983**, *251*, C45–C46 [10.1016/S0022-328X\(00\)98787-4](https://doi.org/10.1016/S0022-328X(00)98787-4). (c) Millington, P. L.; Sowerby, D. B. Preparation and crystal structures of five organoantimony halides; (*p*-tolyl)antimony(III) dichloride and dibromide, diphenylantimony(III) bromide, 2'-diyl)antimony(III) chloride and bis-(2'-chlorobiphenyl-2-yl)antimony(V) trichloride. *J. Organomet. Chem.* **1994**, *480*, 227–234 [10.1016/0022-328X\(94\)87123-X](https://doi.org/10.1016/0022-328X(94)87123-X).

(16) Sheldrick, G. M. *SADABS, Program for empirical X-ray absorption correction*; Bruker-Nonius-Bruker-Nonius : Madison, WI-Madison, WI , 1990.

(17) Sheldrick, G. M. A Short History of SHELX. *Acta Crystallogr., Sect. A: Found. Crystallogr.* **2008**, *A64*, 112–122 [10.1107/S0108767307043930](https://doi.org/10.1107/S0108767307043930).

(18) Vezzulli, L.; Grande, C.; Reid, P. C.; Hélaouët Hélaouët, P.; Edwards, M.; Höfle Höfle, M. G.; Brettar, I.; Colwell, R. R.; Pruzzo, C. Climate influence on *Vibrio* and associated human diseases during the past half-century in the coastal North Atlantic. *Proc. Natl. Acad. Sci. U. S. A.* **2016**, *113*, e5062E5062–e5071E5071 [10.1073/pnas.1609157113](https://doi.org/10.1073/pnas.1609157113).

(19) Cavalli, R.; Donalisio, M.; Bisazza, A.; Cibra, A.; Ranucci, E.; Ferruti, P.; Lembo, D. Enhanced antiviral activity of acyclovir loaded into nanoparticles. *Methods Enzymol.* **2012**, *509*, 1–19 [10.1016/B978-0-12-391858-1.00001-0](https://doi.org/10.1016/B978-0-12-391858-1.00001-0).

(20) Brown, I. D.; Altermatt, D. Bond-valence parameters obtained from a systematic analysis of the inorganic crystal structure database. *Acta Crystallogr., Sect. B: Struct. Sci.* **1985**, *41*, 244–247 [10.1107/S0108768185002063](https://doi.org/10.1107/S0108768185002063).

(21) Mukherjee, H. N. TREATMENT OF CANCER OF THE INTESTINAL TRACT WITH A COMPLEX COMPOUND OF PHOSPHOTUNGSTIC PHOSPHOMOLYBDIC ACIDS AND CAFFEINE Treatment of cancer of the intestinal tract with a complex compound of phosphotungstic phosphomolybdic acids and caffeine. *J. Indian Med. Assoc.* **1965**, *44*, 477–479.